Cascadian Therapeutics Inc. (NASDAQ:CASC) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a note issued to investors on Tuesday.

According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “

Several other brokerages have also recently issued reports on CASC. Cantor Fitzgerald reissued a “hold” rating and issued a $2.00 price objective on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. Cowen and Company reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. Finally, Jefferies Group reissued a “buy” rating on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Cascadian Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $3.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cascadian Therapeutics (NASDAQ:CASC) traded down 8.22% during mid-day trading on Tuesday, hitting $1.34. The company’s stock had a trading volume of 1,143,916 shares. Cascadian Therapeutics has a 12-month low of $0.82 and a 12-month high of $3.75. The firm’s 50-day moving average is $1.33 and its 200-day moving average is $1.17. The company’s market cap is $181.32 million.

Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.14. During the same period in the prior year, the company earned ($0.11) earnings per share. Analysts predict that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

In related news, insider Scott Dunseth Myers bought 45,000 shares of the stock in a transaction on Wednesday, August 17th. The stock was bought at an average price of $1.15 per share, for a total transaction of $51,750.00. Following the completion of the acquisition, the insider now directly owns 107,500 shares in the company, valued at $123,625. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 19.40% of the company’s stock.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Get a free copy of the Zacks research report on Cascadian Therapeutics (CASC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with's FREE daily email newsletter.